PTPI vs. PXMD, KZIA, SNGX, ENSC, DRUG, ARTL, SNPX, GTBP, CPHI, and SONN
Should you be buying Petros Pharmaceuticals stock or one of its competitors? The main competitors of Petros Pharmaceuticals include PaxMedica (PXMD), Kazia Therapeutics (KZIA), Soligenix (SNGX), Ensysce Biosciences (ENSC), Bright Minds Biosciences (DRUG), Artelo Biosciences (ARTL), Synaptogenix (SNPX), GT Biopharma (GTBP), China Pharma (CPHI), and Sonnet BioTherapeutics (SONN). These companies are all part of the "pharmaceutical preparations" industry.
PaxMedica (NASDAQ:PXMD) and Petros Pharmaceuticals (NASDAQ:PTPI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability.
In the previous week, PaxMedica had 2 more articles in the media than Petros Pharmaceuticals. MarketBeat recorded 4 mentions for PaxMedica and 2 mentions for Petros Pharmaceuticals. PaxMedica's average media sentiment score of 0.48 beat Petros Pharmaceuticals' score of -0.48 indicating that Petros Pharmaceuticals is being referred to more favorably in the news media.
4.9% of PaxMedica shares are held by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are held by institutional investors. 57.9% of PaxMedica shares are held by insiders. Comparatively, 36.4% of Petros Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
PaxMedica has a net margin of 0.00% compared to PaxMedica's net margin of -181.87%. PaxMedica's return on equity of -68.90% beat Petros Pharmaceuticals' return on equity.
PaxMedica and Petros Pharmaceuticals both received 1 outperform votes by MarketBeat users.
Petros Pharmaceuticals has higher revenue and earnings than PaxMedica. Petros Pharmaceuticals is trading at a lower price-to-earnings ratio than PaxMedica, indicating that it is currently the more affordable of the two stocks.
PaxMedica presently has a consensus target price of $3.00, indicating a potential upside of 334.78%. Petros Pharmaceuticals has a consensus target price of $4.00, indicating a potential upside of 534.62%. Given PaxMedica's higher possible upside, analysts plainly believe Petros Pharmaceuticals is more favorable than PaxMedica.
PaxMedica has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500. Comparatively, Petros Pharmaceuticals has a beta of 1.91, suggesting that its stock price is 91% more volatile than the S&P 500.
Summary
Petros Pharmaceuticals beats PaxMedica on 9 of the 13 factors compared between the two stocks.
Get Petros Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for PTPI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PTPI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Petros Pharmaceuticals Competitors List
Related Companies and Tools
